K. Wittrup

Part of AbbVie, Inc., BioDisplay Technologies, Inc. is a company that provides medical research services. The company is based in Savoy, IL. The company was founded by Christopher Taron, K. Dane Wittrup. BioDisplay Technologies was acquired by Abbott Laboratories on December 21, 2001 for $7 million.

Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH.

Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA.

Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA.

xCella Biosciences, Inc. engages in the development of protein therapeutics for cancer treatment. Its pipeline is XC-201, a tumor targeting agent. The company was founded by Bob Chen and K. Dane Wittrup and is headquartered in Menlo Park, CA.

Ankyra Therapeutics, Inc. engages in the provision of healthcare services. The company is headquartered in Boston, MA.

76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation.